Instructions for use

The following coverage policy applies to health benefit plans administered by Cigna. Coverage policies are intended to provide guidance in interpreting certain standard Cigna benefit plans and are used by medical directors and other health care professionals in making medical necessity and other coverage determinations. Please note the terms of a customer’s particular benefit plan document may differ significantly from the standard benefit plans upon which these coverage policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a coverage policy.

In the event of a conflict, a customer’s benefit plan document always supersedes the information in the coverage policy. In the absence of federal or state coverage mandates, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of:
1. The terms of the applicable benefit plan document in effect on the date of service
2. Any applicable laws and regulations
3. Any relevant collateral source materials including coverage policies
4. The specific facts of the particular situation

Coverage policies relate exclusively to the administration of health benefit plans. Coverage policies are not recommendations for treatment and should never be used as treatment guidelines.

This evidence-based medical coverage policy has been developed by eviCore, Inc. Some information in this coverage policy may not apply to all benefit plans administered by Cigna.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2016 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

©Copyright 2019 eviCore healthcare
## CMM-211: Spinal Cord Stimulators and Dorsal Root Ganglion Stimulation

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMM-211.1 Definitions</td>
<td>3</td>
</tr>
<tr>
<td>CMM-211.2 Indications</td>
<td>4</td>
</tr>
<tr>
<td>CMM 211.3 Replacement</td>
<td>6</td>
</tr>
<tr>
<td>CMM 211.4 Non-Indications</td>
<td>6</td>
</tr>
<tr>
<td>CMM-211.5 Procedure (CPT®) Codes</td>
<td>8</td>
</tr>
<tr>
<td>CMM-211.6 References</td>
<td>8</td>
</tr>
</tbody>
</table>
CMM-211.1 Definitions

- **Spinal cord stimulation**, also known as dorsal column stimulation or neuromodulation, is a reversible therapy applied for neuropathic pain with techniques that include multi-output implanted pulse generators and a choice of electrodes, some of which can be placed percutaneously. The technical goal of this therapy is to achieve stimulation of paresthesia from the dorsal horn of the spinal cord at a subjectively comfortable level, overlapping an individual's topography of pain. The procedure initially involves a short-term trial (i.e., greater than 48 hours) of percutaneous (temporary) spinal cord stimulation, prior to the subcutaneous (permanent) implantation of the spinal cord stimulation device, to determine whether the spinal cord stimulator device will induce sufficient pain relief to render it medically necessary.

- **High frequency spinal cord stimulation**, also referred to as kilohertz frequency spinal cord stimulation or HF10, is a type of spinal cord stimulation (SCS) providing a higher frequency than traditional spinal cord stimulator systems. The HF10 SCS uses low amplitude, high frequency, and short duration pulses. HF10 SCS does not generate paresthesia and operates at a frequency of 10,000 Hz to provide pain relief in comparison to traditional spinal cord stimulation systems which operate at a frequency in the range of 40-60 Hz and do generate paresthesia. As an alternative to traditional dorsal spinal column stimulation HF10 SCS is proven safe and effective for treatment of chronic, intractable low back and leg pain in individuals with failed back surgery syndrome (FBSS).

- **Dorsal root ganglion (DRG) stimulation** is an emerging method of treatment for neuropathic pain. With DRG stimulation leads are placed percutaneously into the epidural space under fluoroscopic guidance directly over the targeted dorsal root ganglion within the lumbar or sacral region of the spine. Similar to spinal cord stimulation a short-term trial (i.e., greater than 48 hours) is recommended using an external pulse generator; upon success of the trial a permanent pulse generator may then be implanted. At this time, the evidence in the peer-reviewed scientific literature is insufficient to support long-term safety and efficacy. The use of this technology for treatment of pain conditions remains under investigation.

- **Failed back surgery syndrome (FBSS)** is lumbar spinal pain of unknown origin despite surgical intervention or appearing after surgical intervention for spinal pain originally in the same spinal region.
CMM-211.2 Indications

The determination of medical necessity for implantation of a dorsal column spinal cord stimulator is always made on a case-by-case basis.

Chronic Intractable Pain Secondary to Failed Back Surgery Syndrome

- A short-term trial (i.e., greater than 48 hours) spinal cord stimulation (i.e., non high-frequency, high-frequency [HF10 SCS]), is considered medically necessary for the treatment of chronic intractable pain secondary to failed back surgery syndrome (FBSS) with intractable neuropathic leg pain when ALL of the following criteria are met:
  - Failure of at least six consecutive months of physician-supervised conservative medical management (e.g., pharmacotherapy, physical therapy, cognitive therapy, and activity lifestyle modification)
  - Surgical intervention is not indicated or the individual does not wish to proceed with spinal surgery
  - An evaluation by a mental health provider (e.g., a face-to-face assessment with or without psychological questionnaires and/or psychological testing) reveals no evidence of an inadequately controlled mental health problem (e.g., alcohol or drug dependence, depression, psychosis) that would impact perception of pain and/or negatively impact the success of a SCS or contraindicate placement of the device.

- Permanent implantation of a spinal cord stimulator (i.e., non high-frequency, HF10 SCS), is considered medically necessary for the treatment of chronic intractable pain secondary to failed back surgery syndrome (FBSS) with intractable neuropathic leg pain when at least 50% reduction in pain has been demonstrated during a short-term trial of SCS.

Complex Regional Pain Syndrome (CRPS)/Reflex Sympathetic Dystrophy (RSD)

- A short-term trial (i.e., greater than 48 hours) of a non high-frequency dorsal column spinal cord stimulator (SCS) is considered medically necessary for the treatment of chronic, intractable pain secondary to complex regional pain syndrome (CRPS)/reflex sympathetic dystrophy (RSD) when ALL of the following criteria are met:
  - Failure of at least six consecutive months of physician-supervised conservative medical management (e.g., pharmacotherapy, physical therapy, cognitive therapy, and activity lifestyle modification)
  - Surgical intervention is not indicated
  - An evaluation by a mental health provider (e.g., a face-to-face assessment with or without psychological questionnaires and/or psychological testing) reveals no
evidence of an inadequately controlled mental health problem (e.g., alcohol or drug dependence, depression, psychosis) that would impact perception of pain and/or negatively impact the success of SCS or contraindicate placement of the device.

- Permanent implantation of a non high-frequency dorsal column spinal cord stimulator is considered **medically necessary** for the treatment of chronic, intractable pain secondary to complex regional pain syndrome (CRPS)/reflex sympathetic dystrophy (RSD) when at least a 50% reduction in pain has been demonstrated during a short-term trial of SCS.

**Chronic Critical Limb Ischemia (CLI)**

- A short-term trial (i.e., greater than 48 hours) of a non high-frequency dorsal column spinal cord stimulator (SCS) is considered **medically necessary** for the treatment of chronic, intractable pain secondary to chronic critical limb ischemia (CLI) when **BOTH** of the following criteria are met:
  - Failure of available conventional multidisciplinary medical (e.g., pharmacological, physical therapy) and surgical management (e.g., revascularization)
  - An evaluation by a mental health provider (e.g., a face-to-face assessment with or without psychological questionnaires and/or psychological testing reveals no evidence of an inadequately controlled mental health problem (e.g., alcohol or drug dependence, depression, psychosis) that would impact perception of pain and/or negatively impact the success of a SCS or contraindicate placement of the device.

- Permanent implantation of a non high-frequency dorsal column spinal cord stimulator is considered **medically necessary** for the treatment of chronic, intractable pain secondary to chronic critical limb ischemia (CLI) when beneficial clinical response from a temporarily implanted electrode has been demonstrated prior to consideration of permanent implantation.

**Chronic Stable Angina Pectoris**

- A short-term trial (i.e., greater than 48 hours) of a non high-frequency dorsal column spinal cord stimulator (SCS) is considered **medically necessary** for the treatment of chronic, intractable pain secondary to chronic stable angina pectoris/myocardial ischemia when **ALL** of the following criteria are met:
  - Angina pectoris is Canadian Cardiovascular Society (CCS) functional class III or class IV (see Appendix A)
  - Attestation the individual’s treating cardiologist confirms significant coronary artery disease (CAD) and the individual is not a suitable candidate for a revascularization procedure
Optimal pharmacological treatment using anti-anginal medications (e.g., long-acting nitrates, beta-adrenergic blockers, or calcium-channel antagonists) has failed to adequately improve anginal symptoms.

An evaluation by a mental health provider (e.g., a face-to-face assessment with or without psychological questionnaires and/or psychological testing reveals no evidence of an inadequately controlled mental health problem (e.g., alcohol or drug dependence, depression, psychosis) that would impact perception of pain and/or negatively impact the success of SCS or contraindicate placement of the device.

Permanent implantation of a non high-frequency spinal cord stimulator (SCS) is considered medically necessary for the treatment of chronic, intractable pain secondary to chronic stable angina pectoris/myocardial ischemia when a beneficial clinical response from a temporarily implanted electrode has been demonstrated prior to consideration of permanent implantation.

CMM 211.3 Replacement

- The replacement of an existing high frequency or non high-frequency dorsal column spinal cord stimulator (SCS) and/or battery/generator is considered medically necessary for an individual when the existing stimulator and/or battery/generator is malfunctioning, cannot be repaired, and is no longer under warranty.

- Replacement of a functioning non high-frequency dorsal column spinal cord stimulator with a high frequency spinal cord stimulator is considered not medically necessary.

CMM 211.4 Non-Indications

- A high frequency spinal cord stimulator is considered experimental, investigational or unproven for ANY other indication, including CRPS / RSD.

- A non high-frequency spinal cord stimulator (SCS) is considered experimental, investigational or unproven for any other indication including but not limited to:
  - Post-amputation pain (phantom limb pain)
  - Post-herpetic neuralgia
  - Peripheral neuropathy
  - Dysesthesias involving the lower extremities secondary to spinal cord injury

- Dorsal root ganglion stimulation is considered experimental, investigational or unproven for ALL indications.
## Appendix A

**New York Heart Association and Canadian Cardiovascular Society Functional Classifications**

<table>
<thead>
<tr>
<th>Class</th>
<th>New York Heart Association Functional Classification</th>
<th>Canadian Cardiovascular Society Functional Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Patients with cardiac disease but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.</td>
<td>Ordinary physical activity does not cause angina, such as walking and climbing stairs. Angina occurs with strenuous or rapid or prolonged exertion at work or recreation.</td>
</tr>
<tr>
<td>II</td>
<td>Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.</td>
<td>Slight limitation of ordinary activity. Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, in cold, in wind, or under emotional stress, or only during the few hours after awakening. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions.</td>
</tr>
<tr>
<td>III</td>
<td>Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation, dyspnea, or anginal pain.</td>
<td>Marked limitation of ordinary physical activity. Walking one to two blocks on the level and climbing one flight in normal conditions and at a normal pace.</td>
</tr>
<tr>
<td>IV</td>
<td>Patient with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</td>
<td>Inability to carry on any physical activity without discomfort—anginal syndrome may be present at rest.</td>
</tr>
</tbody>
</table>

(Heart Failure Society of America [HFSA], 2006; Gibbons, et al., 2002; American Heart Association [AHA], 1994; Canadian Cardiovascular Society [CCS], 1976).
CMM-211.5 Procedure (CPT®) Codes

This guideline relates to the CPT® code set below. Codes are displayed for informational purposes only.

<table>
<thead>
<tr>
<th>CPT®</th>
<th>Code Description/Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>63650</td>
<td>Percutaneous implantation of neurostimulator electrode array, epidural</td>
</tr>
<tr>
<td>63655</td>
<td>Laminectomy for implantation of neurostimulator electrodes, plate/paddle,</td>
</tr>
<tr>
<td>63685</td>
<td>Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling</td>
</tr>
</tbody>
</table>

This list may not be all inclusive and is not intended to be used for coding/billing purposes. The final determination of reimbursement for services is the decision of the health plan and is based on the individual’s policy or benefit entitlement structure as well as claims processing rules.

CMM-211.6 References

22. Jose De Andres, MD, PhD, FIPP, EDRA, Vicente Monsalve-Dolz, PhD, Gustavo Fabregat-Cid, MD, PhD, Vicente Villanueva-Perez, MD, PhD, Anushik Harutyunyan, Juan Marcos Asensio- Samper, M.D, Nerea Sanchis-Lopex, MD. Prospective, Randomized Blind Effect-on-Outcome Study of Conventional vs High-Frequency Spinal Cord Stimulation in Patients with Pain and Disability Due to Failed Back Surgery Syndrome. Pain Medicine 2017; 18: 2401-2421.
39. Magis D, Allena M, Bolla M, De Pasqua V, Remacle JM, Schoenen J. Occipital nerve stimulation for


44. Marin JC, Goadsby P. Response of SUNCT (short-lasting unilateral neuralgiform headaches with conjunctival injection and tearing), SUNA (short--lasting unilateral neuralgiform headaches with autonomic symptoms) and primary stabbing headaches to occipital nerve stimulation (ONS). Neurology 2010;74:P04.006.


63. Silberstein S, Dodick D, Saper J, Huh B, Slavin KV, Sharan A, et al. Safety and efficacy of peripheral...
nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia 2012;32(16):1165-79.


